Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Gayle Jameson"'
Autor:
Glen J. Weiss, Raoul Tibes, Lisa Blaydorn, Gayle Jameson, Molly Downhour, Erica White, Ivor Caro, Daniel D. Von Hoff
Publikováno v:
Dermatology Reports, Vol 3, Iss 3, Pp e55-e55 (2011)
Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has
Externí odkaz:
https://doaj.org/article/c84cf0cfbb1043739bf6c7c1e6954abb
Autor:
Jonathan B. Fitzgerald, Eliel Bayever, Daryl C. Drummond, Bart S. Hendriks, Jason Cain, Jaeyeon Kim, Stephan G. Klinz, Joshua Prey, Gerald J. Fetterly, Gayle Jameson, Ronald G. Newbold, Jasgit C. Sachdev, Natarajan Raghunand, Ronald L. Korn, Ramesh K. Ramanathan
Correlation between FMX 72-hour signals and binding constant. (A) Mechanistic PK model for tumor deposition of FMX driven by permeability and binding parameters; example for lesion fits for low permeability/low signal retention is shown. (B) Correlat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c922cedfabdb5e7936511ad19ec5a217
https://doi.org/10.1158/1078-0432.22466595
https://doi.org/10.1158/1078-0432.22466595
Autor:
Jonathan B. Fitzgerald, Eliel Bayever, Daryl C. Drummond, Bart S. Hendriks, Jason Cain, Jaeyeon Kim, Stephan G. Klinz, Joshua Prey, Gerald J. Fetterly, Gayle Jameson, Ronald G. Newbold, Jasgit C. Sachdev, Natarajan Raghunand, Ronald L. Korn, Ramesh K. Ramanathan
Includes additional detail concerning methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c6d017bb012e3b5e97c9d238a2a7f6
https://doi.org/10.1158/1078-0432.22466580
https://doi.org/10.1158/1078-0432.22466580
Autor:
Jonathan B. Fitzgerald, Eliel Bayever, Daryl C. Drummond, Bart S. Hendriks, Jason Cain, Jaeyeon Kim, Stephan G. Klinz, Joshua Prey, Gerald J. Fetterly, Gayle Jameson, Ronald G. Newbold, Jasgit C. Sachdev, Natarajan Raghunand, Ronald L. Korn, Ramesh K. Ramanathan
Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identified by quantitative MRI, may predict tumor lesion response to nanoliposomal irinotecan (nal-IRI).Experimental Design: Eligible patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12fd8f6075a55f7e3a9a205895a74ed8
https://doi.org/10.1158/1078-0432.c.6526362
https://doi.org/10.1158/1078-0432.c.6526362
Autor:
Celine Yeh, Mengxi Zhou, Keith Sigel, Gayle Jameson, Ruth White, Rachael Safyan, Yvonne Saenger, Elizabeth Hecht, John Chabot, Stephen Schreibman, Béata Juzyna, Marc Ychou, Thierry Conroy, Tito Fojo, Gulam A Manji, Daniel Von Hoff, Susan E Bates
Publikováno v:
Oncologist
Background Methods for screening agents earlier in development and strategies for conducting smaller randomized controlled trials (RCTs) are needed. Methods We retrospectively applied a tumor growth model to estimate the rates of growth of pancreatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73dea0951d65582600d824ec30d35711
https://europepmc.org/articles/PMC9907043/
https://europepmc.org/articles/PMC9907043/
Autor:
Kuntal Halder, Gayle Jameson, Erkut Borazanci, Amber Vrana, Derek Cridebring, Daniel Von Hoff, Haiyong Han
Publikováno v:
Cancer Research. 82:A041-A041
Pancreatic cancer is a highly lethal disease that is often diagnosed at a late stage, when it has metastasized to other organs. Several therapeutic options have been shown to be effective at significantly shrinking the tumor and improving survival. U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d911147c4e0fa26613d255f635b3dd5c
https://doi.org/10.1158/1538-7445.panca22-a041
https://doi.org/10.1158/1538-7445.panca22-a041
Autor:
Erkut H. Borazanci, Gayle Jameson, Ronald Lee Korn, Lana Caldwell, Karen Ansaldo, Kristin Hendrickson, Katie Marceau, Kevin Gosselin, Daniel D. Von Hoff
Publikováno v:
Cancer Research. 79:CT152-CT152
Background: Effective therapy for the treatment of PDAC remains one of the greatest unmet oncology clinical needs. The addition of C to G and AP has shown promising clinical data in a previously reported study [J Clin Oncol 35, 2017 (suppl 4S; abstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::636883ab5d5924a3847e96d168312fc0
https://doi.org/10.1158/1538-7445.am2019-ct152
https://doi.org/10.1158/1538-7445.am2019-ct152
Autor:
Gayle Jameson, Daniel Von Hoff
Publikováno v:
Supportive Cancer Care ISBN: 9783319248127
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cbd5f61d42313e9b06245aa21747b35
https://doi.org/10.1007/978-3-319-24814-1_10
https://doi.org/10.1007/978-3-319-24814-1_10
Publikováno v:
Journal of Cancer, Vol 3, Iss 1, Pp 7-13 (2012)
Background: There is often a finite progression-free interval of time between one systemic therapy and the next when treating patients with advanced cancer. While it appears that progression-free survival (PFS) between systemic therapies tends to get
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::10e0fa988d2fb2d56581efc20bf0f5f7
http://www.jcancer.org/v03p0007.htm
http://www.jcancer.org/v03p0007.htm
Publikováno v:
Journal of Cancer, Vol 3, Iss 1, Pp 345-353 (2012)
Concomitant medication (CM) use may result in Phase I cancer clinical trial ineligibility due to concern for potential CM-investigational drug interactions or alteration of investigational drug absorption. Few studies have examined the impact of CM u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::04dae0a9e9e5aba2d7546b22c16f2863
http://www.jcancer.org/v03p0345.htm
http://www.jcancer.org/v03p0345.htm